Abstract：
Long non-coding RNAs have emerged as important players in cancer biology. Increasing evidence has uncovered their potency in improving cancer management as they can be used as a credible prognostic and diagnostic biomarker. Recently, DARS-AS1 has gained significant attention for its involvement in facilitating tumor progression. So far, numerous research has been reported its upregulation in different malignancies of human body systems and revealed its association with cancer hallmarks as well as clinicopathological characteristics. Importantly, targeting DARS-AS1 holds promise in cancer therapy. In the current study, we provide an in-depth analysis of its expression status and explore the underlying mechanisms through which DARS-AS1 contributes to tumor initiation, growth, invasion, and metastasis. Additionally, we examine the correlation between DARS-AS1 expression and clinicopathological features of cancer patients, shedding light on its potential as a cancer biomarker. Furthermore, we discuss the therapeutic potential of targeting DARS-AS1 in cancer treatment, highlighting emerging strategies, such as RNA interference and small molecule inhibitors. Boosting the understanding of its functional role can open new avenues for precision medicine, thus resulting in better outcomes for cancer patients.
摘要：
长链非编码RNA已成为癌症生物学中的重要参与者。越来越多的证据揭示了它们在改善癌症管理方面的潜力，因为它们可以用作可靠的预后和诊断生物标志物。最近,DARS-AS1因其参与促进肿瘤进展而受到广泛关注。到目前为止,大量研究已经报道了它在人体系统不同恶性肿瘤中的上调,并揭示了它与癌症标志以及临床病理特征的关联.重要的是,靶向DARS-AS1在癌症治疗中具有希望。在目前的研究中,我们对其表达状态进行了深入分析，并探讨了DARS-AS1促进肿瘤发生的潜在机制，增长,入侵,和转移。此外,我们检查DARS-AS1表达与癌症患者临床病理特征之间的相关性，揭示了它作为癌症生物标志物的潜力。此外，我们讨论了靶向DARS-AS1在癌症治疗中的治疗潜力，突出新兴战略，如RNA干扰和小分子抑制剂。提高对其功能作用的理解可以为精准医学开辟新的途径，从而为癌症患者带来更好的结果。
